



Quality For All

**Tenth of Ramadan for Pharmaceutical Industries
and Diagnostic Reagents (Rameda) S.A.E**

PRESS RELEASE

Equinox Pharma Holding Limited (Equinox), alongside other investors, further increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.

7 March 2022 | Cairo, Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., (RMDA.CA on the EGX), a leading Egyptian pharmaceutical company, announced today that further to the conclusion of the mandatory lock-up period of shares applied to the selling shareholders during its December 2019 IPO, Rameda's main shareholder, Equinox, alongside a GCC-based institutional investor and an executive board member of the company, collectively acquired 6.4% of Rameda's shares through a block trade with a number of pre-IPO shareholders at a total price of EGP 128.6 million. The latest transaction brings Equinox's shareholding in Rameda up by 1.8% to 17.5%, representing an overall increase in Equinox's stake in the company by 4.9% in less than 8 months, and by 38% since the time of the company's IPO.

Commenting on the transaction, Equinox's Managing Director, Shamel Aboul Fadl, said: "Just two years after its listing, and with solid year-end results reported by the company in 2021, we believe that Rameda is on track to generate exceptional growth in both the short and long-term. We look forward to leveraging its currently attractive valuation to ultimately generate long-term and sustainable value to Equinox's portfolio"

"We are especially pleased with the steadfast confidence Equinox has demonstrated time and time again in Rameda's fundamentals, particularly during such a challenging period. As the pharmaceutical industry returns to pre-COVID growth, and with an enhanced portfolio of high-growth products, we look forward to cementing our long-standing partnership with Equinox in this new phase of Rameda's growth story", added Rameda's CEO, Dr. Amr Morsy

-Ends-

Investor Relations Contact:

Yasmine Negm

Rameda's Head of Institutional Investor Relations & Corporate Governance

Email: yasmine.negm@rameda.com

Mobile: +20(0) 1228505050



Quality For All

About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.